Bristol reports success with cancer drug

Associated Press

PRINCETON, N.J.

Bristol-Myers Squibb Co. said Monday that a new study of its highly anticipated melanoma drug improved survival time in patients with advanced skin cancer.

The company said the trial compared patients taking regular chemotherapy with those taking Bristol’s ipilimumab plus chemotherapy. All of the patients had advanced melanoma and had not been treated previously with other drugs.